Results 181 to 190 of about 1,317,331 (364)

AI in Neurology: Everything, Everywhere, All at Once Part 3: Surveillance, Synthesis, Simulation, and Systems

open access: yesAnnals of Neurology, EarlyView.
This final part 3 review builds on the practical applications discussed in part 2 and explores how artificial intelligence (AI) is transforming data management, neurological education, and neurological care across large healthcare networks and datasets. The review also highlights AI's role in real‐world and synthetic data, digital twins, and innovative
Matthew Rizzo
wiley   +1 more source

Pay-Roll Contribution Financed Social Protection Programs in Uruguay [PDF]

open access: yes
In this paper we analyze the recent performance, perspectives and some policy options for two public social security programs in Uruguay: pensions and unemployment insurance.
Alvaro Forteza   +3 more
core  

Toward Natural Limb Function: A New Era in Prosthetic Innovation

open access: yesAnnals of Neurology, EarlyView.
The past decade has witnessed groundbreaking clinical implementation of neuroprosthetic limbs driven by signals from peripheral targets (eg, nerves and muscle) and the brain to restore limb function for individuals with limb loss or impairment. In this review, we highlight recent key clinical trials in peripheral neuroprosthetic interfaces directly ...
Yucheng Tian   +4 more
wiley   +1 more source

The use of trastuzumab affected by health insurance policy in Jiangsu Province of China. [PDF]

open access: yesTransl Cancer Res, 2021
Xia Y   +11 more
europepmc   +1 more source

Public versus Private Insurance with Non-Expected Utility: A Political Economy Argument [PDF]

open access: yes
This paper analyzes the political support for public insurance in the presence of a private insurance alternative. The public insurance is compulsory and offers a uniform insurance policy.
Jean Hindriks
core  

Comparative Safety Profiles of Ocrelizumab and Rituximab in Multiple Sclerosis Treatment Using Real‐World Evidence

open access: yesAnnals of Neurology, EarlyView.
Objective The objective of this study was to compare the long‐term safety profiles of ocrelizumab and rituximab in persons with multiple sclerosis (MS). Methods Using retrospective data from the University of California (UC) Health System, we simulated a target clinical trial. The primary cohort from UC San Francisco (UCSF) and a validation cohort from
Gabriel Cerono   +3 more
wiley   +1 more source

Home - About - Disclaimer - Privacy